Lotfi Benboubker.

For the FIRST Trial Team: Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma For individuals with diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation newly, the typical therapy is melphalan and prednisone combined with either thalidomide or bortezomib .1-10 Lenalidomide can be an immunomodulatory drug that, in conjunction with dexamethasone, is a standard treatment option for patients with multiple myeloma who have received at least one prior therapy as authorized by the Food and Drug Administration and the European Medicines Agency.7-13 In a randomized trial that included both older and younger individuals with newly diagnosed multiple myeloma, lenalidomide plus low-dosage dexamethasone was associated with fewer adverse occasions and an increased rate of general survival at 1 year than lenalidomide plus high-dosage dexamethasone , rendering it an option for patients who are ineligible for stem-cell transplantation.‘By causing the illness and death of employees, the HIV/Helps epidemic reduces the share of skills and experience of the labour force. This loss in human capital is a direct danger to the Millennium Advancement Goals of reducing poverty and promoting sustainable development.’ By far the majority of countries most suffering from HIV/AIDS are in Africa, where the regional typical HIV prevalence can be 7.7 percent. The impact on individuals, households, the culture and the overall economy in Africa and somewhere else was assessed utilizing a number of steps and indicators, several of them developed for this function.

-->